title: [Angiogenesis and thyroid cancer].
abstract: During the last two decades, the understanding of molecular biology of thyroid cancers has greatly improved, and this has permitted the development of novel therapeutic tools in patients with refractory disease. Kinase inhibitors inhibit kinases of the vascular endothelial growth factor (VEGF) receptors, and by doing this inhibit angiogenesis, and some of these agents also inhibit other kinases of the MAPkinase pathway. These inhibitors are effective in differentiated and medullary thyroid cancers, and induce a partial response or a long term stabilisation in more than half of patients.
authors.affiliation: Service de médecine nucléaire et d'oncologie endocrinienne, Paris-Sud et Institut Gustave Roussy, F-94805 Villejuif Cedex, France.
authors.forename: Zelia
authors.initials: Z
authors.lastname: Francis
authors.forename: Eric
authors.initials: E
authors.lastname: Baudin
authors.forename: Sophie
authors.initials: S
authors.lastname: Leboulleux
authors.forename: Martin
authors.initials: M
authors.lastname: Schlumberger
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D006801:Humans; D009389:Neovascularization, Pathologic; D013964:Thyroid Neoplasms / Q000098:blood supply / Q000188:drug therapy*
chemical_list: D020533:Angiogenesis Inhibitors